Education
About Us
Working with TipRanks
Follow Us
Conmed (CNMD)
NYSE:CNMD
CNMD Stock Chart & Stats
$44.35
$0.19(0.28%)
At close: 4:00 PM EST
$44.35
$0.19(0.28%)
Day’s Range― - ―
52-Week Range$35.37 - $64.87
Previous CloseN/A
Volume49.43K
Average Volume (3M)368.83K
Market Cap
$1.28B
Enterprise Value$2.08B
Total Cash (Recent Filing)$40.82M
Total Debt (Recent Filing)$834.94M
Price to Earnings (P/E)18.8
Beta0.49
Next Earnings
May 06, 2026EPS Estimate
0.82Next Dividend Ex-DateN/A
Dividend Yield2.02%
Share Statistics
EPS (TTM)1.43
Shares Outstanding30,833,536
10 Day Avg. Volume284,080
30 Day Avg. Volume368,831
Financial Highlights & Ratios
PEG Ratio-0.41
Price to Book (P/B)1.22
Price to Sales (P/S)0.92
P/FCF Ratio8.35
Enterprise Value/Market Cap1.63
Enterprise Value/Revenue1.51
Enterprise Value/Gross Profit2.80
Enterprise Value/Ebitda11.76
Forecast
1Y Price Target
$49.67Price Target Upside11.99% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)4.44
Revenue Forecast (FY)$1.36B
Bulls Say, Bears Say
Bulls Say
Analyst AlignmentAnalyst estimates were adjusted to reflect the gastroenterology exit in alignment with company guidance, providing confirmation of the updated strategic outlook.
Earnings And Revenue BeatRevenue and earnings per share beat analyst consensus, supported by stronger international sales and easing supply-chain constraints that allowed key product lines to grow.
Portfolio OptimizationAnnouncement of an intentional exit from the gastroenterology business is positioned as a portfolio optimization move expected to improve gross margins and support organic growth.
Bears Say
Analyst Skepticism On GrowthAn analyst maintained a Hold rating until revenue growth becomes consistently in the mid-single-digit range, reflecting skepticism about the company's ability to deliver sustained growth.
Financial GuidanceCompany issued financial guidance below analyst consensus, suggesting weaker revenue expectations and increasing execution risk.
Management UncertaintyDeparture of the chief financial officer without a timeline for naming a replacement increases uncertainty around financial leadership and external communications.
Conmed News
CNMD FAQ
What was Conmed’s price range in the past 12 months?
Conmed lowest stock price was $35.37 and its highest was $64.87 in the past 12 months.
What is Conmed’s market cap?
Conmed’s market cap is $1.28B.
When is Conmed’s upcoming earnings report date?
Conmed’s upcoming earnings report date is May 06, 2026 which is in 60 days.
How were Conmed’s earnings last quarter?
Conmed released its earnings results on Jan 28, 2026. The company reported $1.43 earnings per share for the quarter, beating the consensus estimate of $1.324 by $0.106.
Is Conmed overvalued?
According to Wall Street analysts Conmed’s price is currently Undervalued.
Does Conmed pay dividends?
Conmed pays a Quarterly dividend of $0.2 which represents an annual dividend yield of 2.02%. See more information on Conmed dividends here
What is Conmed’s EPS estimate?
Conmed’s EPS estimate is 0.82.
How many shares outstanding does Conmed have?
Conmed has 30,833,536 shares outstanding.
What happened to Conmed’s price movement after its last earnings report?
Conmed reported an EPS of $1.43 in its last earnings report, beating expectations of $1.324. Following the earnings report the stock price went down -3.567%.
Which hedge fund is a major shareholder of Conmed?
Currently, no hedge funds are holding shares in CNMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Conmed Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$49.67 (11.99% Upside)
$49.67 (11.99% Upside)
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.21%
12-Months-Change
Fundamentals
Return on Equity
6.60%
Trailing 12-Months
Asset Growth
1.87%
Trailing 12-Months
Company Description
Conmed
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. It offers orthopedic surgery products, including TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and PopLok Knotless Suture Anchors, which provide unique clinical solutions to orthopedic surgeons for the repair of soft tissue injuries, as well as supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including diagnostic and therapeutic products for use in gastroenterology procedures, and products for the treatment of diseases of the biliary structures, as well as cardiac monitoring products comprising ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.
CNMD Company Deck
CNMD Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced clear operational and strategic progress—strong adjusted results, meaningful growth in orthopedics, momentum in AirSeal/Buffalo Filter/BioBrace platforms, supply-chain improvements, and solid cash generation—against notable near-term headwinds: a sizeable GAAP earnings decline, tariff-driven margin pressure, and near-term dilution from the GI exit. Management provided constructive 2026 guidance but flagged increased SG&A and R&D investments and tariff impacts that compress near-term EPS. Overall the company appears to be executing a deliberate repositioning for longer-term, higher‑margin growth while accepting short-term earnings trade-offs.View all CNMD earnings summariesCNMD Stock 12 Month Forecast
Average Price Target
$49.67
▲(11.99% Upside)
Technical Analysis
Artivion
―
Integra Lifesciences
―
Ufp Technologies
―
AdaptHealth
―
PROCEPT BioRobotics
―
Ownership Overview
Currently, No data available
---